

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)	Application 10/586,896	Our File No. P/2107-297
	Applicant Ferdinand Hermann Bahlmann	
	Filing Date October 16, 2006	Group Art Unit 1647

## U.S. PATENT DOCUMENTS (not submitted for applications filed after 6/30/03)

Examiner Initial	Document Number	Date MM-YYYY	Name	Class	Sub-class	Filing Date If Appropriate
	US-5,198,417	03-1993	Donahue			
	US-5,354,934	10-1994	Pitt et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM-YYYY	Country	Class	Sub-class	Translation	
						Yes	No
	WO 95/19793	07-1995	WIPO				
	WO 02/053580	07-2002	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	English Translation of German Office Action dated September 4, 2009 corresponding to German Patent Application No.: 10-2004 063 927 .2-41
	S. Masuda et al., "Erythropoietic neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production", International Journal of Hematology, Vol 70, 1999 S. 1-6
	M. Kashiwagi et al., "Hypertension in a pregnancy with renal anemia after recombinant human erythropoietin (rhEPO) therapy", Archives of Gynecology and Obstetrics (2002) 267:54-56
	M. Arcasoy et al., "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing", BIOSIS-Abstract 2002:261552 zu Arcasoy, Blood, 2001, Vol. 98, No. 11, S. 822a-832a
	A. Cases et al., "Recombinated humanerythropoietin treatment in chronic renal failure: effects on hemostatis and vasculature", Drugs of Today, Vol. 36, 2000, No. 8, S. 541-556
	J. Braga et al., "Maternal and perinatal implications of the use of human recombinant erythropoietin", Acta Obstetrica et Gynecologica Scandinavia, Vol. 75, 1996, S. 449-453
	M.V. Alvarez Arroyo et al., "Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation", Journal of the American Society of Nephrology, Vol. 9, 1998-2004
	M. Buemi et al., "Recombinant erythropoietin prevents the progression of atherosclerosis in watanabe rabbits with hereditary hypcholesterolemia", Nephrology Dialysis Transplantation, Vol. 12, 1997, No. 9, S. A190
	J. Llevadot et al., "HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells", The Journal of Clinical Investigation, Vol. 108, 2002, S. 399-405

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.